MARKET

ADYX

ADYX

Adynxx
EXMKT

Real-time Quotes | Nasdaq Last Sale

0.0001
-0.0001
-50.00%
Closed 16:00 05/25 EDT
OPEN
--
PREV CLOSE
0.0001
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.375
52 WEEK LOW
0.0001
MARKET CAP
580.79
P/E (TTM)
-0.0000
1D
5D
1M
3M
1Y
5Y
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera’s existing board members,...
GlobeNewswire · 05/16 12:00
NEXGEL to Report its First Quarter 2022 Financial and Operating Results on May 12, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial and operating results for the fi...
PR Newswire · 05/09 11:30
NEXGEL to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO of NEXGEL, will participate at the Planet...
PR Newswire · 04/28 12:30
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV
LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's Hotel & Casino in Las Vegas, NV.comThe Planet Micr...
ACCESSWIRE · 04/27 13:00
NEXGEL to Present at Maxim Group's 2022 Virtual Growth Conference
NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participat...
PR Newswire · 03/24 12:00
NEXGEL Reports Fourth Quarter and Full Year 2021 Financial Results
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year periods...
PR Newswire · 03/21 20:00
NEXGEL to Report its Fourth Quarter and Full Year 2021 Financial and Operating Results on March 21, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial and operating results for the four...
PR Newswire · 03/17 12:30
NEXGEL Announces Launch of MEDAGEL Bug Bite Relief Patch
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL Bug Bite Relief Patch. These coolin...
PR Newswire · 02/15 12:30
More
No Data
Learn about the latest financial forecast of ADYX. Analyze the recent business situations of Adynxx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADYX stock price target is 2.800 with a high estimate of 2.800 and a low estimate of 2.800.
High2.800
Average2.800
Low2.800
Current 0.0001
EPS
Actual
Estimate
-1.29-0.97-0.64-0.32
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Institutional Holdings
Institutions: 3
Institutional Holdings: 1
% Owned: 0.00%
Shares Outstanding: 5.81M
TypeInstitutionsShares
Increased
0
0
New
1
1
Decreased
0
0
Sold Out
18
90.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.52%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/Director
Dennis Podlesak
Chief Executive Officer/Chief Financial Officer/Director
Rick Orr
Chief Scientific Officer/Director
Julien Mamet
Other
Donald Manning
Director
Stan Abel
Director
Gregory Flesher
Director
Matthew Ruth
Director
Eckard Weber
No Data
No Data
About ADYX
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.

Webull offers kinds of Adynxx Inc stock information, including EXMKT:ADYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADYX stock methods without spending real money on the virtual paper trading platform.